Positive Topline Results from Interim Analysis of Ph 3 ACTION-1 for RYZ101 Announced in Patients with GEP-NETs October 14, 2026
Opamtistomig Granted FDA Fast Track Designation for 1L Advanced or Metastatic Biliary Tract Cancer October 14, 2026
KymaThera Announces $80 Million Series B Financing to Advance K-1728, a Next-Gen Pan-Mutant Selective PI3Kα Inhibitor October 14, 2026
First Patient dosed in Ph 3 RASolute 309 Trial of RASONQUE™ (daraxonrasib) + Zoldonrasib in 1L Metastatic RAS G12D Pancreatic Cancer October 14, 2026
ZENBEXUS (iberdomide) + ZDd Demonstrates Superior PFS vs. SOC in RRMM patients in Ph 3 EXCALIBER-RRMM Study October 14, 2026
EMA validates the MAA for Wevdury® (fuzuloparib) in combination with abiraterone acetate and prednisone/prednisolone for metastatic CRPC patients October 14, 2026
Prelude and Lilly to Evaluate PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer October 14, 2026
Development of vispa-cel in R/R B cell NHL and CB-011 in R/R multiple myeloma to be discontinued October 14, 2026
Epcoritamab + R-CHOP Demonstrates Statistically Significant PFS Improvement in Patients with 1L DLBCL October 14, 2026
Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the US FDA for CRC and NSCLC October 14, 2026
Genezen and InterAct Therapeutics Partner to Advance AAV8-based Gene Therapy for Liver-Dominant Metastatic Breast Cancer October 14, 2026
SRX Global to Acquire CERo Therapeutics, a Company Developing CER 1236 for Hematologic Malignancies October 14, 2026
Tempus Announces Multi-Year Collaboration with Moderna and Merck, to Support Potential Commercialization of Intismeran Autogene October 14, 2026
Carotuximab + Apalutamide Improves PFS in Interim Ph 2 Prostate Cancer trial of ENV-105 October 14, 2026
Statistically Significant Final Three-Year OS Benefit observed for Herlystic-Treated Patients in Ph 2b Pulmonary Metastatic Osteosarcoma Trial October 14, 2026
FAILED TRIAL: AHEAD-MERIT Ph 2/3 trial did not meet first dual primary endpoint of PFS for BNT113 + pembrolizumab vs pembrolizumab in HPV16+ HNSCC patients October 14, 2026
FAILED TRIAL: FURVENT Ph 3 trial of firmonertinib monotherapy in NSCLC patients with EGFR exon 20 insertion mutations did not meet primary PFS endpoint by BICR October 14, 2026
FAILED TRIAL: Ph 2b SURVIVE Trial of SurVaxM in Newly Diagnosed GBM didn’t meet primary endpoint of OS improvement October 14, 2026
FDA Alignment obtained on ENABLE-2 Ph 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated CLL October 14, 2026
Type B meeting provided clear guidance for next steps to prepare IND application for HCW11-018b in solid tumors October 14, 2026
TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer October 14, 2026
